| 08/16 | Australia biotech giant CSL reports profit dip, flags cost spiral | RE |
| 08/16 | Lynparza in combination with abiraterone granted Priority Review in the US for patient.. | AQ |
| 08/16 | AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK | MT |
| 08/16 | AstraZeneca Granted FDA Priority Review for Prostate Cancer Combination Therapy | MT |
| 08/16 | LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US .. | BU |
| 08/16 | ASTRAZENECA : Lynparza in combination with abiraterone granted Priority Review in the US f.. | PU |
| 08/16 | UK's Trade Performance With US Weakens on Strong Dollar, Fuel Imports | DJ |
| 08/16 | FTSE 100 Rises as Strong BHP Results Help Lift Miners | DJ |
| 08/16 | Pound Unmoved After Jobs Data; Latest Inflation Print in Focus | DJ |
| 08/16 | FTSE 100 to Open Higher; Jobs Data Reveals 4.7% Wage Growth | DJ |
| 08/16 | AstraZeneca, Merck & Co.'s Prostate Cancer Drug Wins US FDA's Priority Review Tag | MT |
| 08/16 | Unichem Laboratories Gets US FDA Approval for Generic Mental Disorder Drug | MT |
| 08/16 | AstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDA | DJ |
| 08/15 | ADRs End Mixed, Amarin and AstraZeneca Trade Actively | DJ |
| 08/15 | ASTRAZENECA : Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase .. | PU |
| 08/15 | Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial .. | AQ |
| 08/15 | Serum Institue of India's Poonawalla expects Omicron-specific vaccine in 6 months -NDTV | RE |
| 08/15 | Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for D.. | AQ |
| 08/15 | ENHERTU Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Vers.. | AQ |
| 08/15 | Enhertu approved in the US as the first HER2-directed therapy for patients with previou.. | AQ |
| 08/15 | FTSE 100 ends higher as AstraZeneca offsets commodity losses | RE |
| 08/15 | AstraZeneca Tops FTSE 100 Risers on Drug Progress | DJ |
| 08/15 | European shares edge higher on defensive lift, weak China data stokes worries | RE |
| 08/15 | AstraZeneca, Daiichi Sankyo Say Their Breast Cancer Drug Delayed Disease Progression in.. | MT |
| 08/15 | FTSE 100 Rises as AstraZeneca Gains on Positive Trial Result | DJ |
| 08/15 | FTSE 100 up 0.2%, lifted by Astrazeneca | |
| 08/15 | LONDON STOCK EXCHANGE : FTSE 100 inches higher as AstraZeneca counters China worries | RE |
| 08/15 | EUROPE : European shares edge higher; weak China data stokes worries | RE |
| 08/15 | AstraZeneca-Daiichi's breast cancer drug improves survival in study | RE |
| 08/15 | Enhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says | DJ |
| 08/15 | AstraZeneca's Enhertu Prolongs Progression-free Survival in Late-stage Breast Cancer St.. | MT |
| 08/15 | ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Ve.. | CI |
| 08/12 | Seagen loses arbitration against Daiichi Sankyo over drug technology | RE |
| 08/12 | Seagen loses arbitration ruling against Daiichi Sankyo | RE |
| 08/12 | European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data | MT |
| 08/12 | Sanofi Says First Patient Enrolled in Study to Investigate Protection Against Respirato.. | MT |
| 08/12 | Guardant Health Says FDA Approved Liquid Biopsy Test as Companion Diagnostic for Lung C.. | MT |
| 08/12 | Enhertu approved in the US as the first HER2-directed therapy for patients with previou.. | AQ |
| 08/12 | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe.. | BU |
| 08/12 | ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w.. | PU |
| 08/12 | AstraZeneca, Daiichi Sankyo Receive FDA Approval for Lung Cancer Drug | MT |
| 08/12 | AstraZeneca's Lung Cancer Drug Secures US FDA's Nod | MT |
| 08/12 | Chasing green goals, corporations push car fleet managers toward EVs | RE |
| 08/12 | AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment | DJ |
| 08/11 | Daiichi Sankyo and Astrazeneca’s ENHERTU® Approve in the U.S. as the First HER2 Di.. | CI |
| 08/11 | Acquisition of TeneoTwo for its clinical-stage T-cell engager completed | AQ |
| 08/11 | European ADRs Move Lower in Thursday Trading | MT |
| 08/11 | ASTRAZENECA : Acquisition of TeneoTwo for its clinical-stage T-cell engager completed - Fo.. | PU |
| 08/11 | AstraZeneca Closes Up to $1.3 Billion TeneoTwo Acquisition | MT |
| 08/11 | ASTRAZENECA : Acquisition of TeneoTwo for its clinical-stage T-cell engager completed | PU |
| 08/11 | AstraZeneca PLC completed the acquisition of TeneoTwo, Inc. from TBio, LLC and others. | CI |
| 08/11 | ASTRAZENECA PLC : Ex-dividend day for interim dividend | FA |
| 08/10 | India to start COVID mix-and-match booster vaccines on Friday | RE |
| 08/10 | POSEIDON Phase III post-hoc exploratory analyses presented at WCLC 2022 | AQ |
| 08/09 | ADRs End Mixed | DJ |
| 08/09 | ASTRAZENECA : Gets a Buy rating from JP Morgan | MD |
| 08/09 | AstraZeneca Reports Promising Data From Lung Cancer Trial | DJ |
| 08/09 | AstraZeneca JV's Non-small Cell Lung Cancer Drug Show Favorable Results On Trial | MT |
| 08/08 | ADRs End Mixed; Amarin, AstraZeneca Trade Actively | DJ |
| 08/08 | Transcenta Hires Former AstraZeneca Exec as New Chief Medical Officer | MT |
| 08/08 | Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patie.. | AQ |
| 08/08 | ASTRAZENECA : Gets a Buy rating from JP Morgan | MD |
| 08/08 | TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer pati.. | BU |
| 08/08 | ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w.. | PU |
| 08/08 | AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate | MT |
| 08/08 | AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Tri.. | MT |
| 08/08 | Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-lo.. | AQ |
| 08/08 | HUTCHMED Limited and AstraZeneca PLC Announce Preliminary Results from SAVANNAH Phase I.. | CI |
| 08/08 | Climate change puts Lyme disease in focus for France's Valneva after COVID blow | RE |
| 08/08 | AstraZeneca's Enhertu Breast Cancer Treatment Approved for Use in US | DJ |
| 08/07 | AstraZeneca's Breast Cancer Drug Wins US FDA's First-in-class Approval | MT |
| 08/06 | Daiichi Sankyo and AstraZeneca’s Enhertu® Receives Approval in the U.S. as the Fir.. | CI |
| 08/05 | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe.. | BU |
| 08/05 | ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w.. | PU |
| 08/05 | CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indicat.. | BU |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
